Novo Nordisk A/s Class B · OMXCOP:NOVO_B
Novo Nordisk A/s Class B — Q1 2010 Earnings Presentation
16 slides from Novo Nordisk A/s Class B's earnings presentation, 2010
Slide 1: Investor conference call: First three months of 2010
Investor presentation Investor conference call First three months of 2010
Slide 2: Agenda
Investor presentation First three months of 2010 Slide no 2 Agenda • Introduction (Lars Rebien Sørensen, CEO) • Sales update (Lars Rebien Sørensen, CEO) • Pipeline update (Mads Krogsgaard Thomsen, CSO) • Financial results and outlook (Jesper Brandgaard, CFO) • Questions & answers session
Slide 3: Forward-looking statements
Investor presentation First three months of 2010 Slide no 3 Forward-looking statements Novo Nordisk’s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this document as well as the company’s Annual Report 2009 and Form 20-F, both filed with the SEC in Febr
Slide 4: Highlights and key events
Investor presentation First three months of 2010 Slide no 4 Highlights and key events Market development • Solid launch performance of Victoza® in the US and EU • Modern insulins drive robust sales growth of 9% (11% in local currencies) • North America and International Operations account for more t
Slide 5: Key products continue to drive growth
Investor presentation First three months of 2010 Slide no 5 Key products continue to drive growth – first three months of 2010 Sales as reported Growth analysis HRT Local currencies Growth Share of Norditropin ® +8% growth +5% 3% 8% Diabetes care Modern insulins 20% 69% NovoSeven® +11% Human insulin
Slide 6: North America drives sales growth
Investor presentation First three months of 2010 Slide no 6 North America drives sales growth - first three months of 2010 Sales as reported Growth analysis Japan & Korea -1% North America Local currencies Growth Share of +15% growth 8% International North America 21% 68% Operations +10% Europe 4% 1
Slide 7: Key elements of the US Health Care reform
Investor presentation First three months of 2010 Slide no 7 Key elements of the US Health Care reform Elements with financial impact from 2010 and 2011 Selected additional elements • From 2010 • Medical coverage for 32 million people • Increased mandated Medicaid rebate • Health insurance mandatory
Slide 8: Encouraging start for Victoza in the US
Investor presentation First three months of 2010 Slide no 8 Encouraging start for Victoza® in the US Victoza® share of GLP-1 Encouraging initial market (volume) uptake in the US ® ® Victoza TRx Victoza NRx 25% • Launched in February 2010 23% Share of GLP-1 market (Vol) • Pipeline filling related to
Slide 9: Solid progress of Victoza roll-out in EU
Investor presentation First three months of 2010 Slide no 9 Solid progress of Victoza® roll-out in EU German diabetes market UK diabetes market (value market share) (value market share) Victoza ® Exenatide GLP-1 all Victoza® Exenatide GLP-1 all 4% 5% 4.9% Diabetes market share (value) Diabetes marke
Slide 10: R&D pipeline: Diabetes and obesity
Investor presentation First three months of 2010 Slide no 10 R&D pipeline: Diabetes and obesity Compound Type Indication Status (phase) 1 2 3 Filed Appr. Victoza® Once-daily GLP-1 analogue Type 2 Degludec Ultra LA basal insulin Type 1+2 DegludecPlus Ultra LA basal insulin with a bolus boost Type 1+2
Slide 11: R&D pipeline: Haemostasis
Investor presentation First three months of 2010 Slide no 11 R&D pipeline: Haemostasis Compound Type Indication Status (phase) 1 2 3 Filed Appr. NN1841 rFXIII Congenital FXIII deficiency NN7008 rFVIII Haemophilia A NN1731 FA rFVIIa analogue Haemophilia w. inhibitors NN7128 LA rFVIIa derivative Haemo
Slide 12: R&D pipeline: Other biopharmaceuticals
Investor presentation First three months of 2010 Slide no 12 R&D pipeline: Other biopharmaceuticals Compound Type Indication Phase 1 2 3 Filed Appr. NN8630 LA hGH GHD & AGHD Vagifem® Low Dose Topical product Menopausal symptoms Anti-IL20 Monoclonal antibody PSA / RA Anti-C5aR Monoclonal antibody RA
Slide 13: Financial results
Investor presentation First three months of 2010 Slide no 13 Financial results DKK million Q1 2010 Q1 2009 change Sales 13,674 12,498 9% Gross profit 10,984 9,990 10% Gross margin 80.3% 79.9% Sales and distribution costs 3,984 3,844 4% Percent of sales 29.1% 30.8% Research and development costs 2,13
Slide 14: Key currencies above 2009 average
Investor presentation First three months of 2010 Slide no 14 Key currencies above 2009 average Annual impact on operating 650 650 profit of a 5% movement in Spot rates Quarterly average Annual average currency (DKK million) 2010 USD/DKK 600 600 USD 580 JPY 150 550 550 GBP 80 CNY 100 500 500 CAD 40 4
Slide 15: Financial guidance for 2010
Investor presentation First three months of 2010 Slide no 15 Financial guidance for 2010 Key currency rates • Sales growth expectations: DKK 2009 2010 Current per 100 average average* rate* • Now 7-10% in local currencies USD 536 541 552 • Now around 3 percentage points higher as reported JPY 5.73 5
Slide 16: Investor information
Investor presentation First three months of 2010 Slide no 16 Investor information Share information Investor Relations Novo Nordisk’s B shares are listed contacts on the stock exchange in Novo Nordisk A/S Investor Relations Copenhagen. Its ADRs are listed on Novo Allé, DK-2880 Bagsværd the New York